✦ LIBER ✦

PMS45 Cost-Utility and Budget Impact Analysis of Certolizumab Pegol Plus Methotrexate for the Treatment of Moderate-to-Severe Active Rheumatoid Arthritis in Greece

✍ Scribed by N. Maniadakis; D. Boumpas; G. Kourlaba; P. Christou; I. Anargiros; E. Smets; O Purcaru

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PMS46 Cost-Utility Analysis of Certolizu

✍ R. Villoro; A. Hidalgo; B. Ferro; P. Talavera 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

PMS42 COST-EFFECTIVENESS OF CERTOLIZUMAB

✍ O Purcaru; PC Taylor; P Emery; S Palmer 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

BL1 COST-EFFECTIVENESS, VALUE OF INFORMA

✍ EJ Soini; T Hallinen; M Taiha; V Honkanen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

PMS29 CANADIAN COST-EFFECTIVENESS ANALYS

✍ D Zou; O Desjardins; N Tsao; R Goeree 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

PMS33 COST EFFECTIVENESS OF ABATACEPT IN

✍ F. Becerra Rojas; C. Benites Chacaltana; E.C. Aiello; C. Zingoni; G. Bergman; P. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB